<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0809222595
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2007
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TRACTOCILE solution for injection
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ATOSIBAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        7.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        87.60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="FERRING" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            FERRING
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 612]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrehman Algosaibi G.T.C.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            FERRING INTERNATIONAL CENTER SA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G02CX01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tractocile&reg; contains atosiban. Tractocile&reg; can be used to delay the premature birth of your baby.<br />Tractocile&reg; is used in pregnant adult women, from week 24 to week 33 of the pregnancy.<br />Tractocile&reg; works by making the contractions in your womb (uterus) less strong. It also makes the<br />contractions happen less often. It does this by blocking the effect of a natural hormone in your body<br />called &ldquo;oxytocin&rdquo; which causes your womb (uterus) to contract.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Tractocile&reg;:</strong><br />- If you are less than 24 weeks pregnant.<br />- If you are more than 33 weeks pregnant.<br />- If your waters have broken (premature rupture of your membranes) and you have completed 30 weeks<br />of your pregnancy or more.<br />- If your unborn baby (foetus) has an abnormal heart rate.<br />- If you have bleeding from your vagina and your doctor wants your unborn baby to be delivered<br />straight away.<br />- If you have something called &ldquo;severe pre-eclampsia&rdquo; and your doctor wants your unborn baby to be<br />delivered straight away. Severe pre-eclampsia is when you have very high blood pressure, fluid<br />retention and/or protein in your urine.<br />- If you have something called &ldquo;eclampsia&rdquo; which is similar to &ldquo;severe pre-eclampsia&rdquo; but you would<br />also have fits (convulsions). This will mean your unborn baby needs to be delivered straight away.<br />- If your unborn baby has died.<br />- If you have or could have an infection of your womb (uterus).<br />- If your placenta is covering the birth canal.<br />- If your placenta is detaching from the wall of your womb.<br />- If you or your unborn baby have any other conditions where it would be dangerous to continue with<br />your pregnancy.<br />- If you are allergic to atosiban or any of the other ingredients of this medicine (listed in section 6).<br />Do not use Tractocile if any of the above apply to you. If you are not sure, talk to your doctor, midwife<br />or pharmacist before you are given Tractocile.<br /><strong>Warnings and precautions</strong><br />Talk to your doctor, midwife or pharmacist before you are given Tractocile&reg;:<br />- If you think your waters might have broken (premature rupture of your membranes).<br />- If you have kidney or liver problems.<br />- If you are between 24 and 27 weeks pregnant.<br />- If you are pregnant with more than one baby.<br />- If your contractions start again, treatment with Tractocile&reg; can be repeated up to three more times.<br />- If your unborn baby is small for the time of your pregnancy</p><p>- Your womb may be less able to contract after your baby has been born. This may cause bleeding.<br />- If you are pregnant with more than one baby and/or are given medicines that can delay the birth of<br />your baby, such as medicines used for high blood pressure. This may increase the risk of lung oedema<br />(accumulation of fluid in the lungs).<br />If any of the above apply to you (or you are not sure), talk to your doctor, midwife or pharmacist before<br />you are given Tractocile&reg;.<br /><strong>Children and adolescents</strong><br />Tractocile&reg; has not been studied in pregnant women less than 18 years old.<br /><strong>Other medicines and Tractocile&reg;</strong><br />Tell your doctor, midwife or pharmacist if you are taking, have recently taken or might take any other<br />medicines.<br /><strong>Pregnancy and breast-feeding</strong><br />If you are pregnant and breast-feeding an earlier child, you should stop breast-feeding while you are<br />given Tractocile&reg;..</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tractocile&reg; will be given to you in a hospital by a doctor, nurse or midwife. They will decide how<br />much you need. They will also make sure the solution is clear and free from particles.<br />Tractocile&reg; will be given into a vein (intravenously) in three stages:<br />- The first injection of 6.75 mg in 0.9 ml will be slowly injected into your vein over one minute.<br />- Then a continuous infusion (drip) will be given at a dose of 18 mg per hour for 3 hours.<br />- Then another continuous infusion (drip) at a dose of 6 mg per hour will be given for up to 45 hours, or<br />until your contractions have stopped.<br />Treatment should last no longer than 48 hours in total.<br />Further treatment with Tractocile&reg; can be used if your contractions start again. Treatment with<br />Tractocile&reg; can be repeated up to three more times.<br />During treatment with Tractocile&reg;, your contractions and your unborn baby&rsquo;s heart rate may be<br />monitored.<br />It is recommended that no more than three re-treatments should be used during a pregnancy.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />The side effects seen in the mother are generally of a mild severity. There are no known side effects on<br />the unborn or new-born baby.<br />The following side effects may happen with this medicine:<br /><strong>Very common </strong>(affects more than 1 in 10 people)<br />- Feeling sick (nausea)<br /><strong>Common </strong>(affects less than 1 in 10 people)<br />- Headache<br />- Feeling dizzy<br />- Hot flushes<br />- Being sick (vomiting)<br />- Fast heartbeat<br />- Low blood pressure. Signs may include feeling dizzy or light-headed.<br />- A reaction at the site where the injection was given<br />- High blood sugar<br /><strong>Uncommon </strong>(affects less than 1 in 100 people)<br />- High temperature (fever)<br />- Difficulty sleeping (insomnia)</p><p>- Itching<br />- Rash<br /><strong>Rare </strong>(affects less than 1 in 1,000 people)<br />- Your womb may be less able to contract after your baby has been born. This may cause bleeding.<br />- Allergic reactions<br />You may experience shortness of breath or lung oedema (accumulation of fluid in the lungs),<br />particularly if you are pregnant with more than one baby and/or are given medicines that can delay the<br />birth of your baby, such as medicines used for high blood pressure.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the label after EXP. The expiry date<br />refers to the last day of that month.<br />Store in a refrigerator (2&deg;C - 8&deg;C). Store in the original package in order to protect from light.<br />Once the vial has been opened, the product must be used straight away.<br />Do not use this medicine if you notice particulate matter and discoloration prior to administration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substance is atosiban.<br />- Each vial of Tractocile&reg; 6.75 mg/0.9 ml solution for injection contains atosiban acetate equivalent to<br />6.75 mg of atosiban in 0.9 ml.<br />- The other ingredients are mannitol, hydrochloric acid and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Tractocile® 6.75 mg/0.9 ml solution for injection is a clear, colourless solution without particles. One
pack contains one vial containing 0.9 ml solution.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong><br />Ferring International Center SA,<br />Chemin de la vergognauzas 50,<br />CH-1162 Saint Prex,<br />Switzerland.<br /><strong>Manufacturer</strong><br />Ferring GmbH,<br />Wittland 11,<br />D-24109 Kiel,<br />Germany.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                July,2016
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي تراكتوسيل<strong><sup>&reg;</sup></strong> على أتوسيبان. يمكن استخدام تراكتوسيل<strong><sup>&reg;</sup></strong> لتأخير الولادة المبكرة لطفلك. يُستخدم تراكتوسيل<strong><sup>&reg;</sup></strong> في السيدات الحوامل البالغات، من الأسبوع 24 إلى الأسبوع 33 من الحمل.</p><p>يعمل تراكتوسيل<strong><sup>&reg;</sup></strong> عن طريق تخفيف قوة الانقباضات في الرَّحم لديكِ. كما يقلل من معدل حدوث الانقباضات. وذلك من خلال إعاقة تأثير أحد الهرمونات الطبيعية في جسمك ويُدعى &quot;أوكسيتوسين&quot;، الذي يتسبب في انقباض الرَّحم لديكِ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تستخدمي تراكتوسيل</strong><strong><sup>&reg;</sup></strong><strong> في الحالات الآتية:</strong></p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا لم تبلغ فترة حملكِ 24 أسبوعاً.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا بلغت فترة حملك أكثر من 33 أسبوعاً.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->في حال نزول الماء لديكِ (الانفجار المبكر لجيب المياه/كيس الحمل) وقد أتممتِ 30 أسبوعاً أو أكثر من فترة حملكِ.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كان جنينكِ يعاني من معدل غير طبيعي بضربات القلب.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنتِ تعانين من نزيف بالمهبل ويرغب طبيبكِ في أن يتم توليد جنينكِ على الفور.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنتِ تعانين من شيء يُدعى &quot;مقدمات الارتعاج أو تسمم الحمل الشديد&quot; ويرغب طبيبكِ في أن يتم توليد جنينكِ على الفور. تحدث مقدمات الارتعاج أو تسمم الحمل الشَّديد عندما تعانين من ارتفاع شديد بضغط الدَّم، احتباس السوائل و/ أو وجود بروتينات بالبول لديكِ.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت مُصابة بشيء يُدعى: &quot;الارتعاج&quot;، وهو مماثل لـ&quot;مقدمات الارتعاج أو تسمم الحمل الشَّديد&quot; لكنكِ ستكونين مصابةً أيضاً بنوبات تشنجية. مما سيعني أنه يجب توليد جنينكِ على الفور.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا تُوفي جنينكِ.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنتِ مُصابة أو من المحتمل إصابتكِ بعدوى بالرَّحم.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كانت المشيمة لديكِ تحجب قناة الولادة.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->في حال انفصال المشيمة عن جدار الرحم لديكِ.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->في حال إصابتكِ أو إصابة جنينكِ بحالات أخرى تجعل مواصلة الحمل أمراً خطراً.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنتِ تعانين من حساسية تجاه أتوسيبان أو أي من المكونات الأخرى بهذا الدَّواء (المدرجة في قسم 6).</p><p>لا تستخدمي تراكتوسيل<strong><sup>&reg;</sup></strong> إذا كان أي مما سبق ينطبق عليكِ. إذا لم تكوني متأكدةً، تحدَّثي إلى طبيبكِ أو القابلة أو الصيدلي الخاص بكِ قبل أن يتم إعطاؤكِ تراكتوسيل<strong><sup>&reg;</sup></strong>.</p><p><strong>تحذيرات واحتياطات</strong></p><p>تحدَّثي إلى طبيبكِ أو القابلة أو الصيدلي الخاص بكِ قبل أن يتم إعطاؤكِ تراكتوسيل<strong><sup>&reg;</sup></strong> في الحالات الآتية:</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنتِ تعتقدين أنَّ الماء لديكِ قد نزل (الانفجار المبكر لجيب المياه/ كيس الحمل).</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كان لديكِ مشاكل بالكلى أو الكبد.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كانت فترة حملكِ تتراوح بين 24 و27 أسبوعاً.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنتِ حاملاً بأكثر من طفل واحد.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا بدأت الانقباضات لديكِ مجدداً، يمكن تكرار العلاج بتراكتوسيل<strong><sup>&reg;</sup></strong> لما يصل إلى ثلاث مرات أخرى.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كان جنينكِ صغير الحجم بالنسبة لفترة حملكِ.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->قد تقل قدرة الرحم لديكِ على الانقباض بعد ولادة طفلكِ. وقد يسبب هذا نزيفاً.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنتِ حاملاً بأكثر من طفل واحد و/أو تم إعطاؤك أدوية قد تأخر من ولادة طفلك، مثل الأدوية التي تُستخدم لعلاج ارتفاع ضغط الدَّم. قد يزيد ذلك من خطر الإصابة بوذمة بالرئة (تراكم السوائل بالرئتين).</p><p>إذا كان أيٌّ مما سبق ينطبق عليكِ (أو إذا لم تكوني متأكدةً من ذلك)، تحدَّثي إلى طبيبكِ أو القابلة أو الصيدلي الخاص بكِ قبل أن يتم إعطاؤكِ تراكتوسيل<strong><sup>&reg;</sup></strong>.<strong>&nbsp;</strong></p><p><strong>الأطفال والمراهقون</strong></p><p>لم تتم دراسة تراكتوسيل<strong><sup>&reg;</sup></strong> في السيدات الحوامل ممن يبلغن أقل من 18 عاماً.</p><p><strong>استخدام تراكتوسيل</strong><strong><sup>&reg;</sup></strong><strong> مع الأدوية الأخرى</strong></p><p>يُرجى إبلاغ طبيبكِ أو القابلة أو الصيدلي الخاص بكِ إذا كنتِ تتناولين، أو تناولتِ مؤخراً، أو قد تتناولين أيَّة أدوية أخرى.</p><p><strong>الحمل والرضاعة الطبيعية</strong></p><p>إذا كنتِ حاملاً وتقومين بإرضاع طفل سابق، ينبغي عليكِ التَّوقف عن ممارسة الرضاعة الطبيعيَّة أثناء استخدامكِ لتراكتوسيل<strong><sup>&reg;</sup></strong>.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>سيتم إعطاؤك تراكتوسيل في مستشفى بواسطة طبيب، أو ممرض(ة)، أو قابلة. سوف يقومون بتحديد الكمية التي تحتاجينها. وسيقومون أيضاً بالتَّأكد من أنَّ المحلول صافٍ وخالٍ من الجسيمات.</p><p>سيتم إعطاء تراكتوسيل<strong><sup>&reg;</sup></strong> في الوريد (عن طريق الوريد) على مدار ثلاث مراحل:</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->سيتم إعطاء الحقن الأول والذي يبلغ 6.75 ملغم في 0.9 مللي لتر بشكل بطيء في الوريد لديك على مدى دقيقة واحدة.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ثم سيتم إعطاء تسريب متواصل (تنقيط) بجرعة قدرها 18 ملغم في الساعة لمدة 3 ساعات.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ثم سيتم إعطاء تسريب متواصل (تنقيط) آخر بجرعة قدرها 6 ملغم في الساعة لما يصل إلى 45 ساعة، أو حتى تتوقف الانقباضات لديك.</p><p>ينبغي أَلَّا تتعدى مدة العلاج 48 ساعة إجمالاً.</p><p>يمكن العلاج مجدداً بتراكتوسيل<strong><sup>&reg;</sup></strong> إذا بدأت الانقباضات لديك مرة أخرى. يمكن تكرار العلاج بتراكتوسيل<strong><sup>&reg;</sup></strong> لما يصل إلى ثلاث مرات أخرى.</p><p>أثناء العلاج بتراكتوسيل<strong><sup>&reg;</sup></strong>، قد تتم مراقبة الانقباضات لديك بالإضافة إلى معدل ضربات قلب جنينك. يُوصى بألَّا يتم تكرار العلاج أكثر من ثلاث مرات أثناء الحمل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثله مثل كافة الأدوية، قد يسبب هذا الدَّواء آثاراً جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p>عادةً ما تكون الآثار الجانبية التي تُصاب بها الأم خفيفة من حيث الشدة. ليس هناك آثار جانبية معروفة على الأجنة أو حديثي الولادة.</p><p>قد تحدث الآثار الجانبية التالية مع هذا الدَّواء:<strong>&nbsp;</strong></p><p><strong>شائعة جدًّاً</strong> (تُؤثر على أكثر من شخص واحد من بين كل 10&nbsp;أشخاص)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->شعور بالإعياء (غثيان).&nbsp;</p><p><strong>شائعة</strong> (تُؤثر على الأقل من شخص واحد من بين كل 10 أشخاص)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->صداع.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->شعور بالدوخة.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->هبات ساخنة.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إعياء (قيء).</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ضربات قلب سريعة.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->انخفاض ضغط الدَّم. قد تتضمن العلامات شعور بدوخة أو شعور بخفة الرأس.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تفاعل في موضع الحقن.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->زيادة السكر بالدَّم.&nbsp;</p><p><strong>غير شائعة</strong> (تؤثر على أقل من شخص واحد من بين كل 100 شخص)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ارتفاع درجة الحرارة (حمى).</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->صعوبة النوم (أرق).</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الحكة.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->طفح جلدي.<strong>&nbsp;</strong></p><p><strong>نادرة </strong>(تؤثر على أقل من شخص واحد من بين كل 1000 شخص)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->قد تقل قدرة الرَّحم لديك على الانقباض بعد ولادة طفلك. وقد يسبب هذا نزيفاً.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تفاعلات حساسية.</p><p>قد تعانين من ضيق بالتَّنفس أو وذمة بالرئة (تراكم السوائل بالرئتين)، خاصة إذا كنتِ حاملاً بأكثر من طفل واحد و/أو تم إعطاؤك أدوية قد تأخر من ولادة طفلكِ، مثل الأدوية التي تُستخدم لعلاج ارتفاع ضغط الدَّم.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ابقِ هذا الدواء بعيداً عن متناول و مرأى الأطفال.</p><p>لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على الملصق بعد EXP. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p>يخزن في درجة حرارة من ( 2-8 ) درجة مئوية . يخزن في العبوة الأصلية من أجل الحماية من الضوء.</p><p>&nbsp;</p><p>بمجرد فتح الزجاجة، يجب استخدام الدواء على الفور.</p><p>&nbsp;</p><p>لا تستخدم هذا الدواء إذا لاحظت الجسيمات وتغير اللون قبل الاستخدام.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي أتوسيبان.</p><p>كل زجاجة من التراكتوسيل<strong><sup>&reg;</sup></strong> 6.75 ملغم/ 0.9 مل محلول للحقن تحتوي على أسيتات الاتوسيبان المساوي ل6.75 ملغم من الاتوسيبان في 0.9 مل.</p><p>المواد الاخرى هي مانيتول، حمض الهيدروكلوريك ومياه للحقن.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>تراكتوسيل 6.75 ملغم / 0.9 مل محلول للحقن نقي عديم اللون بدون جزيئات. العلبة الواحدة تحتوي على 0.9 مل محلول للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>الشركة المالكة لحق التسويق: </strong></p><p>فيرنغ انترناشونال سنتر اس اي،</p><p>٥٠ شومان دي لا فيروغوغنوزاز،</p><p>١١٦٢ سانت بريكس، سويسرا.</p><p><strong>&nbsp;</strong></p><p><strong>المصنع</strong><strong> </strong></p><p>فيرينغ جي ام بي اتش،</p><p>ويتلاند11،</p><p>د- 24109 &nbsp;&nbsp;كييل،</p><p>&nbsp;ألمانيا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             تاريخ مراجعة النص: تموز ٢٠١٦
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                TRACTOCILE® 6.75 mg/ 0.9 ml Solution for Injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial of 0.9 ml solution contains 6.75 mg atosiban (as acetate).
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection (injection).
Clear, colourless solution without particles.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tractocile&reg; is indicated to delay imminent pre‑term birth in pregnant adult<br />women with:<br />&minus; Regular uterine contractions of at least 30 seconds duration at a rate of<br />&ge; 4 per 30 minutes.<br />&minus; A cervical dilation of 1 to 3 cm (0‑3 for nulliparas) and effacement of &ge; 50%.<br />&minus; A gestational age from 24 until 33 completed weeks.<br />&minus; A normal foetal heart rate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />Treatment with Tractocile&reg; should be initiated and maintained by a physician<br />experienced in the treatment of pre‑term labour.<br />Tractocile&reg; is administered intravenously in three successive stages:<br />An initial bolus dose (6.75 mg), performed with Tractocile&reg;<br />6.75 mg/ 0.9 ml solution for injection, immediately followed by a<br />continuous high dose infusion (loading infusion 300 micrograms/ min)<br />of Tractocile&reg; 37.5 mg/ 5 ml concentrate for solution for infusion<br />during three hours, followed by a lower dose of Tractocile&reg;<br />37.5 mg/ 5 ml concentrate for solution for infusion (subsequent<br />infusion 100 micrograms/ min) up to 45 hours.<br />The duration of the treatment should not exceed 48 hours. The total<br />dose given during a full course of Tractocile&reg; therapy should preferably<br />not exceed 330.75 mg of atosiban.<br />Intravenous therapy using the initial bolus injection should be started<br />as soon as possible after diagnosis of pre‑term labour. Once the bolus<br />has been injected, proceed with the infusion.<br />In the case of persistence of uterine contractions during treatment with<br />Tractocile&reg;, alternative therapy should be considered.<br />The following table shows the full posology of the bolus injection followed<br />by the infusion:</p><p><img width="671" height="250" alt="" src="data:image/png;base64,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" /></p><p><u>Re-treatment:</u><br />In case a re-treatment with atosiban is needed, it should also commence with<br />a bolus injection of Tractocile&reg; 6.75 mg/ 0.9 ml, solution for injection followed<br />by infusion with Tractocile&reg; 37.5 mg/ 5 ml, concentrate for solution for infusion.<br />Patients with renal or hepatic impairment<br />There is no experience with atosiban treatment in patients with impaired<br /><u>function of the liver or kidneys.</u><br />Renal impairment is not likely to warrant a dose adjustment, since only a<br />small extent of atosiban is excreted in the urine. In patients with impaired<br />hepatic function, atosiban should be used with caution.<br /><u>Paediatric population</u><br />The safety and efficacy of Tractocile&reg; in pregnant women aged less than<br />18 years have not been established.<br />No data are available.<br /><u>Method of administration</u><br />For instructions on preparation of the medicinal product before administration,<br />please refer to &ldquo;Special Precautions for Disposal and Other Handling section&rdquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tractocile® must not be used in the following conditions:
− Gestational age below 24 or over 33 completed weeks.
− Premature rupture of the membranes >30 weeks of gestation.
− Abnormal foetal heart rate.
− Antepartum uterine haemorrhage requiring immediate delivery.
− Eclampsia and severe pre-eclampsia requiring delivery.
− Intrauterine foetal death.
− Suspected intrauterine infection.
− Placenta praevia.
− Abruptio placenta.
− Any other conditions of the mother or foetus, in which continuation of
pregnancy is hazardous.
− Hypersensitivity to the active substance(s) or to any of the listed excipients.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>When atosiban is used in patients in whom premature rupture of membranes<br />cannot be excluded, the benefits of delaying delivery should be balanced<br />against the potential risk of chorioamnionitis.<br />There is no experience with atosiban treatment in patients with impaired<br />function of the liver or kidneys.<br />Renal impairment is not likely to warrant a dose adjustment, since only a<br />small extent of atosiban is excreted in the urine. In patients with impaired<br />hepatic function, atosiban should be used with caution.<br />There is only limited clinical experience in the use of atosiban in multiple<br />pregnancies or the gestational age group between 24 and 27 weeks, because<br />of the small number of patients treated. The benefit of atosiban in these<br />subgroups is therefore uncertain.<br />Re-treatment with Tractocile&reg; is possible, but there is only limited clinical<br />experience available with multiple re-treatments, up to 3 re-treatments.<br />In case of intrauterine growth retardation, the decision to continue or<br />reinitiate the administration of Tractocile&reg; depends on the assessment of<br />foetal maturity.<br />Monitoring of uterine contractions and foetal heart rate during administration<br />of atosiban and in case of persistent uterine contractions should be<br />considered.<br />As an antagonist of oxytocin, atosiban may theoretically facilitate uterine<br />relaxation and postpartum bleeding therefore blood loss after delivery should<br />be monitored. However, inadequate uterus contraction postpartum was not<br />observed during the clinical trials.<br />Multiple pregnancy and medicinal products with tocolytic activity like<br />calcium channel blockers and betamimetics are known to be associated<br />with increased risk of pulmonary oedema. Therefore, atosiban should be used<br />with caution in case of multiple pregnancy and/ or concomitant administration<br />of other medicinal products with tocolytic activity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>It is unlikely that atosiban is involved in cytochrome P450 mediated drug‑drug<br />interactions as in vitro investigations have shown that atosiban is not a<br />substrate for the cytochrome P450 system, and does not inhibit the drug<br />metabolizing cytochrome P450 enzymes.<br />Interaction studies have been performed with labetalol and betamethasone<br />in healthy, female volunteers. No clinically relevant interaction was found<br />between atosiban and bethamethasone or labetalol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Atosiban should only be used when pre‑term labour has been diagnosed<br />between 24 and 33 completed weeks of gestation. If during pregnancy<br />the woman is already breast-feeding an earlier child, then breast-feeding<br />should be discontinued during treatment with Tractocile&reg;, since the release<br />of oxytocin during breast-feeding may augment uterine contractility, and<br />may counteract the effect of tocolytic therapy.<br />In atosiban clinical trials no effects were observed on breast-feeding. Small<br />amounts of atosiban have been shown to pass from plasma into the breast<br />milk of breast-feeding women.<br />Embryo‑foetal toxicity studies have not shown toxic effects of atosiban.<br />No studies were performed that covered fertility and early embryonic<br />development.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not relevant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Possible adverse reactions of atosiban were described for the mother during<br />the use of atosiban in clinical trials. In total 48% of the patients treated<br />with atosiban experienced adverse reactions during the clinical trials. The<br />observed adverse reactions were generally of a mild severity. The most<br />commonly reported adverse reaction in the mother is nausea (14 %).<br />For the newborn, the clinical trials did not reveal any specific adverse reactions<br />of atosiban. The infant adverse reactions were in the range of normal variation<br />and were comparable with both placebo and betamimetic group incidences.<br />The frequency of adverse reactions listed below is defined using the following<br />convention: Very common (&ge;1/10); Common (&ge;1/100 to &lt;1/10); Uncommon<br />(&ge;1/1,000 to &lt;1/100); Rare (&ge;1/10,000 to &lt;1/1,000).<br />Within each frequency grouping, adverse reactions are presented<br />in order of decreasing seriousness.<br /><strong>Very Common</strong>: Nausea.<br /><strong>Common</strong>: Hyperglycaemia, Headache, Dizziness, Tachycardia,<br />Hypotension, Hot flush, Vomiting, Injection site reaction.<br /><strong>Uncommon</strong>: Insomnia, Pruritis, Rash, Pyrexia.<br /><strong>Rare</strong>: Allergic reaction, Uterine haemorrhage, uterine atony.<br /><u>Post-marketing experience:</u><br />Respiratory events like dyspnoea and pulmonary oedema,<br />particularly in association with concomitant administration of other<br />medicinal products with tocolytic activity, like calcium antagonists<br />and betamimetics, and/or in women with multiple pregnancy, have<br />been reported post-marketing.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Few cases of atosiban overdosing were reported, they occurred without any<br />specific signs or symptoms.<br />There is no known specific treatment in case of an overdose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other gynecologicals, ATC code: G02CX01.<br />Tractocile &reg; contains atosiban (INN), a synthetic peptide<br />([Mpa1,D‑Tyr(Et)2,Thr4,Orn8]-oxytocin) which is a competitive antagonist of<br />human oxytocin at receptor level. In rats and guinea pigs, atosiban was shown<br />to bind to oxytocin receptors, to decrease the frequency of contractions and<br />the tone of the uterine musculature, resulting in a suppression of uterine<br />contractions. Atosiban was also shown to bind to the vasopressin receptor,<br />thus inhibiting the effect of vasopressin. In animals atosiban did not exhibit<br />cardiovascular effects.<br />In human pre‑term labour, atosiban at the recommended dosage<br />antagonises uterine contractions and induces uterine quiescence. The<br />onset of uterus relaxation following atosiban is rapid, uterine contractions<br />being significantly reduced within 10 minutes to achieve stable uterine<br />quiescence (&le; 4 contractions/ hour) for 12 hours.<br />Phase III clinical trials (CAP‑001 studies) include data from 742 women<br />who were diagnosed with pre‑term labour at 23&ndash;33 weeks of gestation<br />and were randomised to receive either atosiban (according to this labelling)<br />or &beta;-agonist (dose-titrated).<br />Primary endpoint: the primary efficacy outcome was the proportion of women<br />remaining undelivered and not requiring alternative tocolysis within 7 days<br />of treatment initiation. The data show that 59.6% (n=201) and 47.7% (n=163)<br />of atosiban- and &beta;-agonist-treated women (p=0.0004), respectively, were<br />undelivered and did not require alternative tocolysis within 7 days of starting<br />treatment. Most of the treatment failures in CAP‑001 were caused by poor<br />tolerability. Treatment failures caused by insufficient efficacy were significantly<br />(p=0.0003) more frequent in atosiban (n=48, 14.2%) than in the &beta;-agonisttreated<br />women (n=20, 5.8%).<br />In the CAP‑001 studies the probability of remaining undelivered and not<br />requiring alternative tocolytics within 7 days of treatment initiation was<br />similar for atosiban and beta-mimetics treated women at gestational age<br />of 24‑28 weeks. However, this finding is based on a very small sample<br />(n=129 patients).<br />Secondary endpoints: secondary efficacy parameters included the proportion<br />of women remaining undelivered within 48 h of treatment initiation. There<br />was no difference between the atosiban and betamimetic groups with regard<br />to this parameter.<br />Mean (SD) gestational age at delivery was the same in the two groups: 35.6 (3.9)<br />and 35.3 (4.2) weeks for the atosiban and &beta;-agonist groups, respectively<br />(p=0.37). Admission to a neonatal intensive care unit (NICU) was similar<br />for both treatment groups (approximately 30%), as was length of stay and<br />ventilation therapy.<br />Mean (SD) birth weight was 2491 (813) grams in the atosiban group and<br />2461 (831) grams in the &beta;-agonist group (p=0.58).<br />Foetal and maternal outcome did apparently not differ between the atosiban<br />and the &beta;-agonist group, but the clinical studies were not powered enough<br />to rule out a possible difference.<br />Of the 361 women who received atosiban treatment in the phase III studies,<br />73 received at least one retreatment, 8 received at least 2 re-treatments and<br />2 received 3 re-treatments.<br />As the safety and efficacy of atosiban in women with a gestational age of less<br />than 24 completed weeks has not been established in controlled randomised<br />studies, the treatment of this patient group with atosiban is not recommended.<br />In a placebo-controlled study, foetal/ infant deaths were 5/295 (1.7%) in the<br />placebo group and 15/288 (5.2%) in the atosiban group, of which two occurred<br />at five and eight months of age. Eleven out of the 15 deaths in the atosiban<br />group occurred in pregnancies with a gestational age of 20 to 24 weeks,<br />although in this subgroup patient distribution was unequal (19 women on<br />atosiban, 4 on placebo). For women with a gestational age greater than<br />24 weeks there was no difference in mortality rate (1.7% in the placebo group<br />and 1.5% in the atosiban group).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In healthy non-pregnant subjects receiving atosiban infusions<br />(10 to 300 micrograms/ min over 12 hours), the steady state plasma<br />concentrations increased proportionally to the dose.<br />The clearance, volume of distribution and half‑life were found to be<br />independent of the dose.<br />In women in pre‑term labour receiving atosiban by infusion<br />(300 micrograms/ min for 6 to 12 hours), steady state plasma concentrations<br />were reached within one hour following the start of the infusion (mean<br />442 &plusmn; 73 ng/ ml, range 298 to 533 ng/ ml).<br />Following completion of the infusion, plasma concentration rapidly declined<br />with an initial (t&alpha;) and terminal (t&beta;) half‑life of 0.21 &plusmn; 0.01 and 1.7 &plusmn; 0.3 hours,<br />respectively. Mean value for clearance was 41.8 &plusmn; 8.2 litres/ h. Mean value of<br />volume of distribution was 18.3 &plusmn; 6.8 litres. Plasma protein binding of atosiban<br />is 46 to 48% in pregnant women. It is not known whether the free fraction in<br />the maternal and foetal compartments differs substantially. Atosiban does<br />not partition into red blood cells.<br />Atosiban passes the placenta. Following an infusion of 300 micrograms/ min in<br />healthy pregnant women at term, the foetal/ maternal atosiban concentration<br />ratio was 0.12.<br />Two metabolites were identified in the plasma and urine from human<br />subjects. The ratios of the main metabolite M1 (des‑(Orn8, Gly‑NH2 9)‑[Mpa1,<br />D‑Tyr(Et)2, Thr4]-oxytocin) to atosiban concentrations in plasma were 1.4 and<br />2.8 at the second hour and at the end of the infusion respectively. It is not<br />known whether M1 accumulates in tissues. Atosiban is found in only small<br />quantities in urine, its urinary concentration is about 50 times lower than<br />that of M1. The proportion of atosiban eliminated in faeces is not known.<br />The main metabolite M1 is approximately 10 times less potent than atosiban<br />in inhibiting oxytocin-induced uterine contractions in vitro. Metabolite M1 is<br />excreted in milk.<br />There is no experience with atosiban treatment in patients with impaired<br />function of the liver or kidneys.<br />Renal impairment is not likely to warrant a dose adjustment, since only a<br />small extent of atosiban is excreted in the urine. In patients with impaired<br />hepatic function, atosiban should be used with caution.<br />It is unlikely that atosiban inhibits hepatic cytochrome P450 isoforms in<br />humans.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>N/A</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol<br />Hydrochloric acid 1M<br />Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be<br />mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                See outer carton
Once the vial has been opened, the product must be used immediately.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C‑8&deg;C). Store in the original package in order to<br />protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>One vial of solution for injection contains 0.9 ml solution, corresponding to<br />6.75 mg atosiban.<br />Colourless glass vials, clear borosilicated (type I) sealed with grey siliconised<br />bromo‑butyl rubber stopper, type I, and flip‑off cap of polypropylene and<br />aluminium.<br />The pack contains one Unit.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The vials should be inspected visually for particulate matter and discoloration<br />prior to administration.<br />Preparation of the initial intravenous injection:<br />Withdraw 0.9 ml of a 0.9 ml labelled vial of Tractocile&reg; 6.75 mg/ 0.9 ml,<br />solution for injection and administer slowly as an intravenous bolus dose<br />over one minute, under adequate medical supervision in an obstetric unit. The<br />Tractocile&reg; 6.75 mg/ 0.9 ml, solution for injection should be used immediately.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufacturing Site: Ferring GmbH, Wittland 11, 24109 Kiel, Germany.
Marketing Authorization Holder: Ferring International Center SA, Chemin
de la Vergognausaz 50, 1162 Saint Prex, Switzerland.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July 2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>